Abstract
TMS therapy for depression delivered to the dorsolateral prefrontal cortex (DLPFC) aims to modulate activity in the subgenual cingulate cortex (SGC). However, these regions lack direct axonal connections, and the neuroanatomical mechanisms underlying the therapy’s efficacy remain unknown. Here, we use connectome modelling to map polysynaptic fibre pathways from the DLPFC to the SGC that are associated with TMS treatment response in depression. We show that polysynaptic communication through the structural connectome is correlated with treatment response in two independent cohorts of patients treated with TMS to the left DLPFC (r = –0.56, p = 0.0018; r = –0.52, p = 0.0047), and that DLPFC sites of stronger negative functional connectivity to the SGC are connected to it via shorter fibre pathways. Our results shed light onto the neuroanatomical basis of TMS therapy for depression and pave the way for brain stimulation protocols based on polysynaptic communication via the connectome.
Competing Interest Statement
L.C., R.F.H. and A.Z. are involved in a not-for-profit clinical neuromodulation centre (Queensland Neurostimulation Centre) that offers neuroimaging-guided neurotherapeutics. In the last 3 years P.B.F. has received reimbursement for educational activities from Otsuka Australia Pharmaceutical Pty Ltd and equipment for research from Brainsway Ltd.
Clinical Trial
ACTRN12610001071011
Funding Statement
C.S. is supported by the ARC Discovery Early Career Researcher Award Fellowship. A.Z. is supported by the ARC Future Fellowship. R.F.H. is supported by the NHMRC Emerging Leadership Investigator Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Alfred Hospital Human Research Ethics Committee gave ethical approval for this work (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336262).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos